Traws Pharma, Inc. (NASDAQ:TRAW) Receives Average Recommendation of “Reduce” from Brokerages

Traws Pharma, Inc. (NASDAQ:TRAW) has received a consensus rating of “Reduce” from the five brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $1.00.

Several analysts have commented on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Traws Pharma in a research report on Tuesday, August 18th. LADENBURG THALM/SH SH cut shares of Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Citigroup downgraded Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th.

Traws Pharma Price Performance

Shares of Traws Pharma stock opened at $0.63 on Wednesday. The firm has a market cap of $9.62 million, a PE ratio of -0.36 and a beta of 1.60. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27. The stock has a fifty day moving average price of $0.54 and a 200-day moving average price of $1.07.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. As a group, equities analysts anticipate that Traws Pharma will post -1.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Traws Pharma stock. Seven Fleet Capital Management LP bought a new stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 49,260 shares of the company’s stock, valued at approximately $56,000. Seven Fleet Capital Management LP owned about 0.62% of Traws Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products.

Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections.